| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| CCTE_Deisenroth_5AR_NBTE_ratio | Kidney | Human | 6716 | SRD5A2 | Inhibitory | 49.95 μM |
| NVS_ADME_hCYP1A2 | | Human | 1544 | CYP1A2 | Loss | 1.15 μM |
| NVS_ADME_hCYP2B6 | | Human | 1555 | CYP2B6 | Loss | 0.41 μM |
| NVS_ADME_hCYP2C19 | | Human | 1557 | CYP2C19 | Loss | 1.19 μM |
| NVS_GPCR_g5HT4 | Brain | Guinea pig | 100135548 | Htr4 | Loss | 19.0 μM |
| NVS_GPCR_gLTD4 | Lung | Guinea pig | 100135514 | Cysltr1 | Loss | 1.24 μM |
| NVS_GPCR_hAdrb1 | | Human | 153 | ADRB1 | Loss | 1.57 μM |
| NVS_GPCR_hNK2 | | Human | 6865 | TACR2 | Loss | 1.29 μM |
| NVS_MP_rPBR | Kidney | Rat | 24230 | Tspo | Loss | 0.31 μM |
| NVS_NR_hPXR | | Human | 8856 | NR1I2 | Loss | 0.7 μM |
| NVS_OR_gSIGMA_NonSelective | Brain | Guinea pig | 100135589 | Sigmar1 | Loss | 25.0 μM |
| NVS_TR_hNET | | Human | 6530 | SLC6A2 | Loss | 0.34 μM |
| ATG_AP_1_CIS | Liver | Human | 2353|3725 | FOS|JUN | Activatory | 30.05 μM |
| ATG_BRE_CIS | Liver | Human | 4086 | SMAD1 | Activatory | 141.71 μM |
| ATG_CRE_CIS | Liver | Human | 10488 | CREB3 | Activatory | 76.02 μM |
| ATG_DR4_LXR_CIS | Liver | Human | 7376|10062 | NR1H2|NR1H3 | Inhibitory | 30.68 μM |
| ATG_DR5_RAR_CIS | Liver | Human | 5914|5915|5916 | RARA|RARB|RARG | Inhibitory | 148.99 μM |
| ATG_E_Box_CIS | Liver | Human | 7391 | USF1 | Activatory | 18.89 μM |
| ATG_EGR_CIS | Liver | Human | 1958 | EGR1 | Inhibitory | 124.62 μM |
| ATG_Ets_CIS | Liver | Human | 2113 | ETS1 | Inhibitory | 158.01 μM |
| ATG_FoxO_CIS | Liver | Human | 2308|2309 | FOXO1|FOXO3 | Inhibitory | 151.62 μM |
| ATG_GATA_CIS | Liver | Human | 2623 | GATA1 | Activatory | 157.54 μM |
| ATG_GLI_CIS | Liver | Human | 2735 | GLI1 | Inhibitory | 152.7 μM |
| ATG_HIF1a_CIS | Liver | Human | 3091 | HIF1A | Activatory | 174.64 μM |
| ATG_HNF6_CIS | Liver | Human | 3175 | ONECUT1 | Inhibitory | 100.0 μM |
| ATG_HSE_CIS | Liver | Human | 3297 | HSF1 | Activatory | 101.04 μM |
| ATG_IR1_CIS | Liver | Human | 9971 | NR1H4 | Inhibitory | 63.17 μM |
| ATG_ISRE_CIS | Liver | Human | 3659 | IRF1 | Activatory | 81.33 μM |
| ATG_MRE_CIS | Liver | Human | 4520 | MTF1 | Inhibitory | 147.86 μM |
| ATG_Myb_CIS | Liver | Human | 4602 | MYB | Inhibitory | 161.55 μM |
| ATG_Myc_CIS | Liver | Human | 4609 | MYC | Inhibitory | 83.69 μM |
| ATG_NF_kB_CIS | Liver | Human | 4790 | NFKB1 | Inhibitory | 27.19 μM |
| ATG_NFI_CIS | Liver | Human | 4774 | NFIA | Inhibitory | 158.3 μM |
| ATG_NRF1_CIS | Liver | Human | 4899 | NRF1 | Inhibitory | 175.02 μM |
| ATG_NRF2_ARE_CIS | Liver | Human | 4780 | NFE2L2 | Inhibitory | 183.66 μM |
| ATG_Oct_MLP_CIS | Liver | Human | 5451 | POU2F1 | Inhibitory | 144.06 μM |
| ATG_p53_CIS | Liver | Human | 7157 | TP53 | Activatory | 137.15 μM |
| ATG_Pax6_CIS | Liver | Human | 5080 | PAX6 | Inhibitory | 137.14 μM |
| ATG_PBREM_CIS | Liver | Human | 9970 | NR1I3 | Activatory | 166.39 μM |
| ATG_PXRE_CIS | Liver | Human | 8856 | NR1I2 | Inhibitory | 160.53 μM |
| ATG_Sox_CIS | Liver | Human | 6656 | SOX1 | Activatory | 100.0 μM |
| ATG_Sp1_CIS | Liver | Human | 6667 | SP1 | Activatory | 149.78 μM |
| ATG_SREBP_CIS | Liver | Human | 6720 | SREBF1 | Inhibitory | 157.48 μM |
| ATG_TCF_b_cat_CIS | Liver | Human | 6932|6934|51176|83439 | TCF7|TCF7L2|LEF1|TCF7L1 | Activatory | 118.25 μM |
| ATG_VDRE_CIS | Liver | Human | 7421 | VDR | Inhibitory | 116.73 μM |
| ATG_Xbp1_CIS | Liver | Human | 7494 | XBP1 | Inhibitory | 139.41 μM |
| ATG_PXR_TRANS | Liver | Human | 8856 | NR1I2 | Gain | 49.57 μM |
| BSK_3C_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 34.77 μM |
| BSK_3C_ICAM1 | Vascular | Human | 3383 | ICAM1 | Inhibitory | 34.93 μM |
| BSK_3C_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 31.17 μM |
| BSK_3C_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 30.61 μM |
| BSK_3C_MIG | Vascular | Human | 4283 | CXCL9 | Inhibitory | 36.9 μM |
| BSK_3C_Thrombomodulin | Vascular | Human | 7056 | THBD | Inhibitory | 29.79 μM |
| BSK_3C_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 20.0 μM |
| BSK_3C_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 20.3 μM |
| BSK_3C_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 28.91 μM |
| BSK_4H_Eotaxin3 | Vascular | Human | 10344 | CCL26 | Inhibitory | 32.34 μM |
| BSK_4H_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 24.65 μM |
| BSK_4H_Pselectin | Vascular | Human | 6403 | SELP | Inhibitory | 20.0 μM |
| BSK_4H_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 26.35 μM |
| BSK_4H_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 32.45 μM |
| BSK_4H_VEGFRII | Vascular | Human | 3791 | KDR | Inhibitory | 26.8 μM |
| BSK_BE3C_IP10 | Lung | Human | 3627 | CXCL10 | Inhibitory | 25.46 μM |
| BSK_BE3C_MIG | Lung | Human | 4283 | CXCL9 | Inhibitory | 32.31 μM |
| BSK_BE3C_MMP1 | Lung | Human | 4312 | MMP1 | Inhibitory | 25.54 μM |
| BSK_BE3C_PAI1 | Lung | Human | 5054 | SERPINE1 | Inhibitory | 27.85 μM |
| BSK_BE3C_TGFb1 | Lung | Human | 7040 | TGFB1 | Inhibitory | 17.91 μM |
| BSK_BE3C_uPAR | Lung | Human | 5329 | PLAUR | Inhibitory | 22.57 μM |
| BSK_CASM3C_HLADR | Vascular | Human | 3122 | HLA-DRA | Inhibitory | 31.15 μM |
| BSK_CASM3C_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 20.0 μM |
| BSK_CASM3C_LDLR | Vascular | Human | 3949 | LDLR | Inhibitory | 35.36 μM |
| BSK_CASM3C_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 31.6 μM |
| BSK_CASM3C_MCSF | Vascular | Human | 1435 | CSF1 | Inhibitory | 24.36 μM |
| BSK_CASM3C_MIG | Vascular | Human | 4283 | CXCL9 | Inhibitory | 33.28 μM |
| BSK_CASM3C_SAA | Vascular | Human | 6288 | SAA1 | Inhibitory | 28.76 μM |
| BSK_CASM3C_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 20.0 μM |
| BSK_CASM3C_uPAR | Vascular | Human | 5329 | PLAUR | Inhibitory | 31.12 μM |
| BSK_CASM3C_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 30.57 μM |
| BSK_hDFCGF_VCAM1 | Skin | Human | 7412 | VCAM1 | Inhibitory | 1.56 μM |
| BSK_LPS_CD40 | Vascular | Human | 958 | CD40 | Inhibitory | 30.4 μM |
| BSK_LPS_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 34.79 μM |
| BSK_LPS_IL1a | Vascular | Human | 3552 | IL1A | Inhibitory | 20.0 μM |
| BSK_LPS_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 29.66 μM |
| BSK_LPS_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 29.52 μM |
| BSK_LPS_MCSF | Vascular | Human | 1435 | CSF1 | Inhibitory | 30.26 μM |
| BSK_LPS_TissueFactor | Vascular | Human | 2152 | F3 | Inhibitory | 27.63 μM |
| BSK_LPS_VCAM1 | Vascular | Human | 7412 | VCAM1 | Inhibitory | 28.05 μM |
| BSK_SAg_CD38 | Vascular | Human | 952 | CD38 | Inhibitory | 31.7 μM |
| BSK_SAg_CD40 | Vascular | Human | 958 | CD40 | Inhibitory | 32.0 μM |
| BSK_SAg_CD69 | Vascular | Human | 969 | CD69 | Inhibitory | 20.0 μM |
| BSK_SAg_Eselectin | Vascular | Human | 6401 | SELE | Inhibitory | 32.56 μM |
| BSK_SAg_IL8 | Vascular | Human | 3576 | CXCL8 | Inhibitory | 32.5 μM |
| BSK_SAg_MCP1 | Vascular | Human | 6347 | CCL2 | Inhibitory | 28.43 μM |
| BSK_SAg_MIG | Vascular | Human | 4283 | CXCL9 | Inhibitory | 36.29 μM |
| ATG_mPPARg_XSP2 | Liver | Human | 19016 | Pparg | Gain | 38.33 μM |
| ATG_hPPARg_XSP2 | Liver | Human | 5468 | PPARG | Gain | 33.94 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | Human | 367 | AR | Loss | 0.51 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | Human | 367 | AR | Loss | 0.31 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | Human | 1588 | CYP19A1 | Loss | 0.22 μM |
| TOX21_ELG1_LUC_Agonist | Kidney | Human | 79915 | ATAD5 | Gain | 18.08 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 0.06 μM |
| TOX21_RORg_LUC_CHO_Antagonist | Ovary | Chinese hamster | 6097 | RORC | Loss | 0.17 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 0.22 μM |
| TOX21_RAR_LUC_Antagonist | Embryo | Mouse | 5914 | RARA | Loss | 0.36 μM |
| TOX21_CAR_LUC_Antagonist | Liver | Human | 9970 | NR1I3 | Loss | 0.35 μM |
| TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 | Breast | Human | 2099 | ESR1 | Loss | 0.29 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.29 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.39 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 0.26 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 0.21 μM |
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | Human | 4086 | SMAD1 | Loss | 0.15 μM |
| TOX21_KISS1R_HEK293_WT | Kidney | Human | 84634 | KISS1R | Gain | 19.69 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | Human | 367 | AR | Loss | 0.14 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | Human | 367 | AR | Loss | 0.25 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | Human | 1588 | CYP19A1 | Loss | 0.07 μM |
| TOX21_ELG1_LUC_Agonist | Kidney | Human | 79915 | ATAD5 | Gain | 60.59 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 0.07 μM |
| TOX21_VDR_BLA_Antagonist_ratio | Kidney | Human | 1591|7421 | CYP24A1|VDR | Loss | 38.31 μM |
| TOX21_RORg_LUC_CHO_Antagonist | Ovary | Chinese hamster | 6097 | RORC | Loss | 0.23 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 0.17 μM |
| TOX21_RAR_LUC_Antagonist | Embryo | Mouse | 5914 | RARA | Loss | 0.45 μM |
| TOX21_TSHR_HTRF_Agonist_ratio | Kidney | Human | 7253 | TSHR | Gain | 70.84 μM |
| TOX21_CAR_LUC_Antagonist | Liver | Human | 9970 | NR1I3 | Loss | 0.27 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.27 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.3 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 0.42 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 0.48 μM |
| TOX21_TRHR_HEK293_Antagonist | Kidney | Human | 7201 | TRHR | Loss | 20.42 μM |
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | Human | 4086 | SMAD1 | Loss | 0.16 μM |
| TOX21_p450_CYP2D6_Antagonist | | Human | 1565 | CYP2D6 | Loss | 57.47 μM |
| TOX21_p450_CYP1A2_Antagonist | | Human | 1544 | CYP1A2 | Loss | 26.05 μM |
| TOX21_AChE_ms_Antagonist | | Human | 43 | ACHE | Loss | 79.63 μM |
| TOX21_hERG_U2OS_Antagonist | Bone | Human | 3757 | KCNH2 | Loss | 38.31 μM |
| TOX21_AR_BLA_Agonist_ratio | Kidney | Human | 367 | AR | Gain | 22.01 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | Human | 367 | AR | Loss | 0.16 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | Human | 367 | AR | Loss | 0.23 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | Human | 1588 | CYP19A1 | Loss | 0.08 μM |
| TOX21_ELG1_LUC_Agonist | Kidney | Human | 79915 | ATAD5 | Gain | 44.01 μM |
| TOX21_TR_LUC_GH3_Antagonist | Pituitary gland | Rat | 7067|7068 | THRA|THRB | Loss | 22.43 μM |
| TOX21_VDR_BLA_Antagonist_ratio | Kidney | Human | 1591|7421 | CYP24A1|VDR | Loss | 39.08 μM |
| TOX21_RORg_LUC_CHO_Antagonist | Ovary | Chinese hamster | 6097 | RORC | Loss | 0.19 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | Human | 367 | AR | Loss | 0.21 μM |
| TOX21_RAR_LUC_Antagonist | Embryo | Mouse | 5914 | RARA | Loss | 0.32 μM |
| TOX21_TSHR_HTRF_Agonist_ratio | Kidney | Human | 7253 | TSHR | Gain | 43.61 μM |
| TOX21_CAR_LUC_Antagonist | Liver | Human | 9970 | NR1I3 | Loss | 0.32 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.23 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | Human | 2101 | ESRRA | Loss | 0.28 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | Human | 2100 | ESR2 | Loss | 0.22 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | Human | 5241 | PGR | Loss | 0.22 μM |
| TOX21_TRHR_HEK293_Antagonist | Kidney | Human | 7201 | TRHR | Loss | 22.28 μM |
| TOX21_SBE_BLA_Antagonist_ratio | Kidney | Human | 4086 | SMAD1 | Loss | 0.18 μM |
| TOX21_p450_CYP2D6_Antagonist | | Human | 1565 | CYP2D6 | Loss | 47.95 μM |
| TOX21_p450_CYP1A2_Antagonist | | Human | 1544 | CYP1A2 | Loss | 19.41 μM |
| TOX21_AChE_ms_Antagonist | | Human | 43 | ACHE | Loss | 82.26 μM |
| TOX21_AChE_Antagonist | | Human | 43 | ACHE | Loss | 67.95 μM |
| TOX21_hERG_U2OS_Antagonist | Bone | Human | 3757 | KCNH2 | Loss | 39.08 μM |
| Assay Name | Tissue | Organism | Target Gene ID | Target HGNC Symbol | Response | AC50 Value |
|---|
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist | Bone | Human | 367 | AR | Loss | 19.78 μM |
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist | Bone | Human | 367 | AR | Gain | 50.0 μM |
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist | Bone | Human | 367 | AR | Gain | 64.41 μM |
| APR_HepG2_MitoticArrest_24hr | Liver | Human | 3020 | H3-3A | Activatory | 25.18 μM |
| APR_HepG2_StressKinase_24hr | Liver | Human | 3725 | JUN | Activatory | 85.04 μM |
| APR_HepG2_MitoticArrest_72hr | Liver | Human | 3020 | H3-3A | Activatory | 23.52 μM |
| APR_HepG2_P-H2AX_72hr | Liver | Human | 3014 | H2AX | Activatory | 27.09 μM |
| APR_HepG2_StressKinase_72hr | Liver | Human | 3725 | JUN | Inhibitory | 30.99 μM |
| OT_AR_ARSRC1_0480 | Kidney | Human | 367|6714 | AR|SRC | Gain | 25.03 μM |
| OT_AR_ARSRC1_0960 | Kidney | Human | 367|6714 | AR|SRC | Gain | 59.58 μM |
| OT_ERa_GFPERaERE_0120 | Cervix | Human | 2099 | ESR1 | Gain | 77.72 μM |
| OT_ERa_GFPERaERE_0480 | Cervix | Human | 2099 | ESR1 | Gain | 92.48 μM |
| ACEA_AR_antagonist_80hr | Prostate | Human | 367 | AR | Loss | 25.58 μM |
| TOX21_FXR_BLA_Antagonist_ratio | Kidney | Human | 9971 | NR1H4 | Loss | 0.21 μM |
| TOX21_PPARd_BLA_Antagonist_ratio | Kidney | Human | 5467 | PPARD | Loss | 0.15 μM |
| TOX21_H2AX_HTRF_CHO_Agonist_ratio | Ovary | Chinese hamster | 3014 | H2AX | Gain | 0.27 μM |
| TOX21_SHH_3T3_GLI3_LUC_Antagonist | Embryo | Mouse | 6469 | SHH | Loss | 0.32 μM |
| TOX21_HSE_BLA_Agonist_ratio | Cervix | Human | 3297 | HSF1 | Gain | 0.03 μM |
| TOX21_FXR_BLA_Antagonist_ratio | Kidney | Human | 9971 | NR1H4 | Loss | 0.08 μM |
| TOX21_PPARd_BLA_Antagonist_ratio | Kidney | Human | 5467 | PPARD | Loss | 0.08 μM |
| TOX21_H2AX_HTRF_CHO_Agonist_ratio | Ovary | Chinese hamster | 3014 | H2AX | Gain | 0.37 μM |
| TOX21_SHH_3T3_GLI3_LUC_Antagonist | Embryo | Mouse | 6469 | SHH | Loss | 0.24 μM |
| TOX21_p53_BLA_ms_rat_ratio | Intestinal | Human | 7157 | TP53 | Gain | 54.04 μM |
| TOX21_PPARd_BLA_Antagonist_ratio | Kidney | Human | 5467 | PPARD | Loss | 0.11 μM |
| TOX21_H2AX_HTRF_CHO_Agonist_ratio | Ovary | Chinese hamster | 3014 | H2AX | Gain | 0.31 μM |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.